Credit Suisse Group Cuts Ra Pharmaceuticals (RARX) Price Target to $14.00
Ra Pharmaceuticals (NASDAQ:RARX) had its target price reduced by Credit Suisse Group from $16.00 to $14.00 in a report issued on Tuesday. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s price objective indicates a potential upside of 115.38% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. ValuEngine cut shares of Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Royal Bank of Canada reaffirmed a “buy” rating and issued a $18.00 target price on shares of Ra Pharmaceuticals in a report on Tuesday, December 5th. Finally, BMO Capital Markets upped their target price on shares of Ra Pharmaceuticals in a report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $20.10.
Shares of Ra Pharmaceuticals (RARX) opened at $6.50 on Tuesday. Ra Pharmaceuticals has a 52-week low of $5.80 and a 52-week high of $27.84. The company has a market cap of $144.81, a PE ratio of -2.65 and a beta of 2.15.
ILLEGAL ACTIVITY WARNING: “Credit Suisse Group Cuts Ra Pharmaceuticals (RARX) Price Target to $14.00” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/15/credit-suisse-group-cuts-ra-pharmaceuticals-rarx-price-target-to-14-00.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.